About Hua Medicine
Hua Medicine R&D Pipeline
   Products Pre-clinical Ph I Ph II Ph III

Dorzagliatin (HMS5552)

Drug Naive T2D

Dorzagliatin + Metformin

T2D with metformin tolerance

Dorzagliatin + DPPIV

Obese T2D

Dorzagliatin + SGLT-2

Metabolic Syndrome

Dorzagliatin + Insulin

Late Stage T2D

Dorzagliatin + GLP-1

Obese T2D

mGLUR5 NAM

PD-LID
Hua is a leading, clinical stage innovative drug development company in China focused on novel therapies for the treatment of diabetes. Founded by an experienced group of entrepreneurs and international investment firms, Hua advanced a first-in-class oral drug for the treatment of Type 2 Diabetes into NDA enabling stage and started 2 Phase 3 trials in China for drug naive and metformin treated T2D patients. The company also has initiated product life-cycle management studies of this novel diabetes drug, and advanced knowledge in personalized diabetes care. Hua's strategy is to leverage the cost-efficient and high-quality drug development capabilities available in China, while working very closely with disease experts in China and rest of world to advance diabetes care solutions for global patients.
News